Perioperative enfortumab vedotin + pembrolizumab tied to improved outcomes with bladder cancer

Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy compared with surgery alone, according to…

Continue Reading

News Source: medicalxpress.com